Clincosm LogoSign in Get a demo

Triple Negative Breast Cancer

Showing NaN - NaN of 17
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Triple Negative Breast Cancer Trial in Worldwide (Atezolizumab, Paclitaxel, Dose-dense Doxorubicin or dose-dense Epirubicin)

Active, not recruiting
  • Triple Negative Breast Cancer
  • Concord, California
  • +429 more
Dec 12, 2022

Triple Negative Breast Cancer Trial in Beijing (Eribulin Mesylate, Lobaplatin)

Recruiting
  • Triple Negative Breast Cancer
  • Beijing, Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Sep 15, 2022

NSCLC, Triple Negative Breast Cancer Trial in China (Datopotamab Deruxtecan (Dato-DXd))

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Triple Negative Breast Cancer
  • Datopotamab Deruxtecan (Dato-DXd)
  • Beijing, China
  • +27 more
Aug 11, 2022

Triple Negative Breast Cancer Trial in Beijing (SHR-1210 + Apatinib +Fluzoparib)

Completed
  • Triple Negative Breast Cancer
  • SHR-1210 + Apatinib +Fluzoparib
  • Beijing, Beijing, China
    Beijing Cancer Hosptial
Aug 9, 2022

Triple Negative Breast Cancer Trial in Worldwide (biological, device, other)

Recruiting
  • Triple Negative Breast Cancer
  • adagloxad simolenin combined with OBI-821
  • +2 more
  • Harbor City, California
  • +97 more
Jul 5, 2022

Advanced Solid Tumor, Cholangiocarcinoma, Biliary Tract Cancer Trial in Beijing, Jinan, Shanghai (TT-00420, Combination Product:

Not yet recruiting
  • Advanced Solid Tumor
  • +10 more
  • Beijing, China
  • +3 more
Feb 14, 2022

Advanced Solid Tumors, Triple Negative Breast Cancer Trial in Houston, Beijing (TT-00420)

Active, not recruiting
  • Advanced Solid Tumors
  • Triple Negative Breast Cancer
  • Houston, Texas
  • +1 more
Oct 25, 2021

Triple Negative Breast Cancer Trial in Beijing (oral etoposide + anlotinib)

Recruiting
  • Triple Negative Breast Cancer
  • oral etoposide + anlotinib
  • Beijing, China
    Cancer Institute & Hospital. Chinese Academy of Medical Sciences
Jul 15, 2021

Advanced High-grade Ovarian Cancer, Triple Negative Breast Cancer Trial in China (Pamiparib)

Active, not recruiting
  • Advanced High-grade Ovarian Cancer
  • Triple Negative Breast Cancer
  • Hefei, Anhui, China
  • +25 more
Jun 16, 2021

Triple Negative Breast Cancer Trial in Beijing (Epirubicin or Pirarubicin, Cyclophosphamide)

Recruiting
  • Triple Negative Breast Cancer
  • Beijing, Beijing, China
    Cancer Hospital & Institute Chinese Academy of Medical Sciences
Jun 16, 2020

Triple Negative Breast Cancer Patients

Recruiting
  • Triple Negative Breast Cancer
    • Beijing, Beijing, China
      Peking Union Medical College Hospital
    Nov 14, 2019

    Triple Negative Breast Cancer Trial in Beijing (JS001,an engineered anti-PD-1 antibody, Nab-Paclitaxel, Placebo)

    Suspended
    • Triple Negative Breast Cancer
    • JS001，an engineered anti-PD-1 antibody
    • +2 more
    • Beijing, China
      The fifth medical center of PLA general hospital
    Aug 6, 2019

    Triple Negative Breast Cancer Trial in Beijing (Epirubicin, Cyclophosphamide, Paclitaxel)

    Recruiting
    • Triple Negative Breast Cancer
    • Beijing, Beijing, China
      National Cancer Center, Cancer Hospital/Chinese Academy of Medic
    Mar 20, 2019

    HER2-Negative Breast Cancer, Triple Negative Breast Cancer, Breast Cancer Trial in China (E7389 (Eribulin Mesylate), Vinorelbine

    Completed
    • HER2-Negative Breast Cancer
    • +4 more
    • E7389 (Eribulin Mesylate)
    • Vinorelbine injection
    • Bengbu, Anhui, China
    • +34 more
    Aug 27, 2018

    Triple Negative Breast Cancer Trial in Aurora, Indianapolis, Beijing (ENMD-2076)

    Completed
    • Triple Negative Breast Cancer
    • Aurora, Colorado
    • +2 more
    Jun 23, 2017

    Malignant Mesothelioma, Pancreatic Cancer, Ovarian Tumor Trial in Beijing (anti-meso-CAR vector transduced T cells)

    Unknown status
    • Malignant Mesothelioma
    • +5 more
    • anti-meso-CAR vector transduced T cells
    • Beijing, Beijing, China
      Biotherapeutic Department and Pediatrics Department of Chinese P
    Oct 19, 2015

    Triple Negative Breast Cancer Trial in Beijing (Paclitaxel plus carboplatin, Paclitaxel and epirubicin)

    Unknown status
    • Triple Negative Breast Cancer
    • Paclitaxel plus carboplatin
    • Paclitaxel and epirubicin
    • Beijing, Beijing, China
      Cancer institute &Hospital，Chinese Academy of Medical Sciences
    Nov 15, 2011